Get the Stockscreener App
33.43
0.24%
0.08
After Hours:
34.10
0.67
+2.00%
Metsera Inc stock is traded at $33.43, with a volume of 2.38M.
It is up +0.24% in the last 24 hours and up +13.51% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$33.35
Open:
$33.99
24h Volume:
2.38M
Relative Volume:
2.27
Market Cap:
$3.51B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.51%
1M Performance:
+13.51%
6M Performance:
+13.21%
1Y Performance:
+0.00%
1-Day Range:
$32.24
$34.01
1-Week Range:
$31.01
$36.24
52-Week Range:
$12.30
$47.40
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
33.43 | 3.50B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.65 | 96.11B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.13 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
428.14 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.15 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.52 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-20-25 | Initiated | Wells Fargo | Overweight |
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
Watch for Bullish Crossover in Metsera Inc.Quick Gain Stock Watch With Indicators Reviewed - metal.it
Metsera, Inc. Reports Q2 2025 Financial Progress - TipRanks
What is Metsera Inc. company’s growth strategyPhenomenal trading returns - Jammu Links News
What are the latest earnings results for Metsera Inc.Unlock your portfolio’s hidden potential - Jammu Links News
Why is Metsera Inc. stock attracting strong analyst attentionUnlock expert insights for smarter investing - Jammu Links News
How volatile is Metsera Inc. stock compared to the marketBuild a diversified portfolio for risk mitigation - Jammu Links News
Is it the right time to buy Metsera Inc. stockFree Stock Market Beginners Guide - Jammu Links News
What are Metsera Inc. company’s key revenue driversUnlock powerful trading techniques - Jammu Links News
What are analysts’ price targets for Metsera Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What catalysts could drive Metsera Inc. stock higher in 2025Get timely alerts on market opportunities - Jammu Links News
Is Metsera Inc. a growth stock or a value stockGet exclusive market analysis for investors - Jammu Links News
How strong is Metsera Inc. company’s balance sheetBuild wealth with high-performing stocks - Jammu Links News
We're Hopeful That Metsera (NASDAQ:MTSR) Will Use Its Cash Wisely - Yahoo Finance
Metsera Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingDay Trading Signals With High Precision Reviewed - metal.it
Metsera, Inc. Lock-Up Agreement Expiration: 30-JUL-2025 - AInvest
Metsera stock rating reiterated by Cantor Fitzgerald ahead of key updates - Investing.com Nigeria
Guggenheim Maintains Metsera(MTSR.US) With Buy Rating, Maintains Target Price $62 - 富途牛牛
Metsera, Inc. Poised for Growth: Anticipated Catalysts and Clinical Trial Success Drive Buy Rating - TipRanks
What makes Metsera Inc. stock price move sharplyBuy Low Sell High Stock Watch Strategy in Focus - metal.it
Metsera reports Q2 EPS (66c), consensus (68c) - TipRanks
Metsera, Inc.: Why Shares Are on the Rise - TipRanks
Metsera Posts Narrower Q2 Loss - MarketScreener
Metsera shares tumble as quarterly loss worse than expected By Investing.com - Investing.com Canada
Metsera shares tumble as quarterly loss worse than expected - Investing.com
Metsera Reports Second Quarter 2025 Financial Results and Continued Portfolio Progress - GlobeNewswire
Metsera Obesity Drug Achieves 8.4% Weight Loss in 5 Weeks; Multiple Trial Results Coming in 2025 - Stock Titan
Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why - Yahoo Finance
Chartists Watching For Breakout in Metsera Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Should I hold or sell Metsera Inc. stock in 2025Stock Market Review That Work - jammulinksnews.com
What is the dividend policy of Metsera Inc. stockExpert guidance for superior capital growth - Jammu Links News
Does Metsera Inc. stock perform well during market downturnsUnmatched market performance - jammulinksnews.com
What institutional investors are buying Metsera Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.10%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):